Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-07-09

Clinical Trial Update: A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor [Phase 2]

View source ↗

Summary

Phase 2 trial of pembrolizumab in thymic epithelial tumors has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Samsung Medical Center | Conditions: Thymic Epithelial Tumors | Phase 2 | Status: COMPLETED